📰 Weekly Medical Innovation Digest
October 28 – November 3, 2025

AI in Healthcare

Gene Therapy

Radioligand Theranostics

Insights & Perspective

Milestones

🤖 Artificial Intelligence in Healthcare

Channel 4's Arti: UK's first AI news presenter launched, stirring up more existential dread among the BBC's human anchors. Source
OpenAI's Atlas Browser: Directly challenges Google, deeply integrated with LLM-based search and research tools. Source
MaLMIC Forum (Oct 31): Machine learning for multimodal brain imaging and clinical translation goes mainstream at MGH. Source
MICCAI 2025: Swiss teams sweep 3 top competitions with self-supervised learning for medical imaging and segmentation. Source
Stanford Virtual Scientist Lab: AI agents autonomously solve biological research problems, now with snarky commentary module. Source
Isomorphic Labs: AI-designed CRISPR drugs enter human trials. Source

Retron Multi-Mutation Editing (Oct 25): Simultaneous correction of multiple disease mutations in vivo. Source
ADA-SCID Safety Study: 100% OS, >95% cured in 7.5-year pediatric gene therapy cohort. Source
UCD-NIBRT Manufacturing: €2M invested to slash gene therapy production costs and improve scalability. Source
Eli Lilly/Adverum Acquisition: Major gene therapy pipeline expansion. Source
Immusoft Fast Track: FDA accepts expedited pathway for neural-centric gene delivery. Source
Lexeo FDA Accelerated Pathway: New gene therapy receives regulatory boost for cardiac indication. Source

Trial/Company	Status	Notes
Retron Multi-Mutation	Preclinical	Mice & primate models, multi-locus efficacy
ADA-SCID (Europe)	Phase III	First 7.5yr cohort, pediatric population
Immusoft Neural Gene	FDA Fast Track	MPS1, neural disease focus

Pluvicto in Early Prostate Cancer: PSMAddition Phase III: 28% boost in progression-free survival (PFS) in hormone-sensitive PCa. Source
LUNAR Trial: PSMA RLT + XRT: 17.6 vs 7.4 months PFS (UCLA, ASTRO 2025). Source
Mayo Clinic Alpha-RPT: First-in-human GPC3-targeted alpha-emitter for HCC, initial patients dosed. Source
Clarity Pharmaceuticals: Pan-cancer FAP-targeting radioligand, expanding beyond prostate. Source
OECD-NEA RLT Infrastructure: Global survey on supply/demand gaps and regulatory frustration. Source

AI now acts as both assistant and autonomous research partner (cue human existential crisis and job security queries).
Gene therapy moves beyond ultra-rare to common disorders—finally, an excuse for investors to pretend they understand N-of-1 studies.
Theranostics rapidly expands past PSMA-prostate to pan-cancer, multi-indication approaches.
Emerging supply chain bottlenecks (Lu-177, Ac-225 isotopes), workforce development, and global equity issues—because nothing says "innovation" like regulatory migraine.

Contact your local medical director for advice, existential comfort, or Pluvicto memes.